350 руб
Журнал «Технологии живых систем» №7 за 2011 г.
Статья в номере:
Токсичность препаратов L-аспарагиназы и экспериментальные подходы к ее снижению
Ключевые слова: L-аспарагиназа токсичность острый лимфобластный лейкоз
Авторы:
В.С. Покровский, М.В. Покровская, С.С. Александрова, Н.М. Омельянюк, Н.Н. Соколов
Аннотация:
В работе проанализированы экспериментальные и клинические данные о побочных эффектах L-аспарагиназ различного происхождения и подходах к их изучению. Описаны экспериментальные методы снижения токсичности, в том числе путем генно-инженерной и химической модификации ферментов. C клинической точки зрения перспективным направлением является поиск и изучение L-аспарагиназ из новых источников
Страницы: 11-19
Список источников
  1. Абакумова О.Ю., Подобед О.В., Борисова А.А. и др. Противоопухолевая активность L-ас¬парагиназы из Yersinia pseudotuberculosis // Биомедицинская химия. 2008. Т. 54. № 6. С. 712 - 719.
  2. Гладилина Ю.А., Соколов Н.Н., Красоткина Ю.В. Клонирование экспрессия и выделение L-аспарагиназы Helicobacter pylori // Биомедицинская химия. 2008. Т. 54. № 4. С. 482 - 486.
  3. Кучумова А.В., Красоткина Ю.В., Хасигов П.З., Соколов Н.Н. Пегилирование рекомбинантной аспарагиназы Erwinia carotovora полиэтиленгликолем 5000 // Биомедицинская химия. 2007. Т.53. № 1. С. 107 - 111.
  4. Трещалина Е.М. Противоопухолевая активность веществ природного происхождения // М.: Практическая медицина. 2005. 270 с.
  5. Abuchowski A., Kazo G.M., Verhoest C.R. Jr. et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates // Cancer Biochem Biophys. 1984. V. 7(2). P. 175 - 186.
  6. Agrawal N.R., Bukowski R.M., Rybicki L.A. et al. A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma // Cancer. 2003. V. 98(1). P. 94 - 99.
  7. Alvarez O.A., Zimmerman G. Pegaspargase-induced pancreatitis // Med. Pediatr Oncol. 2000. V. 34(3). P. 200 - 205.
  8. Appel I.M., Hop W.C., Pieters R. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases // Blood Coagul. Fibrinolysis. 2006. V. 17. P. 139-146.
  9. Asselin B.L., Whitin J.C., Coppola D.J. et al. Comparative pharmacokinetic studies of three asparaginase preparations // J. Clin. Oncol. 1993. № 11. P. 1780 - 1786.
  10. Avramis V.I., Panosyan E.H. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future // Clin. Pharmacokinet. 2005. V. 44. P. 367 - 393.
  11. Avramis V.I., Tiwari P.N. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia // Int. J. Nanomed. 2006. V. 1. № 3. P. 241 - 254.
  12. Bendich A., Kafkewitz D., Abuchowski A., Davis F.F. Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice // Clin. Exp. Immunol. 1982. V. 48. P. 273 - 278.
  13. Boyd J.W., Phillips A.W. Purification and properties of L-asparaginase from Serratia marcescens // J. Bacteriol. 1971. V. 106. № 2. P. 578 - 587.
  14. Broome J.D. Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects // Nature. 1961. V. 191. P. 1114 - 1115.
  15. Cameron J.L., Capuzzi D.M., Zuidema G.D., Margolis S. Acute pancreatitis with hyperlipidemia: evidence for a persistent defect in lipid metabolism // Am. J. Med. 1974. V. 56. P. 482 - 487.
  16. Capizzi R.L., Bertino J.R., Handschumaker R.E. L-asparaginase // Annu. Rev. Med. 1970. V. 21. P.431 - 444.
  17. Capizzy R.L., Cheng Y.C. Therapy of neoplasia with asparaginase / Enzymes as drug. Ed. Holcenberg J.S., Roberts J. NY, John Wiley and Sons. 1981. P. 1 - 24.
  18. Cappelletty D., Chiarelli L.R., Pasquetto M.V. et al. Helicobacter pylori L-asparaginase: A promising new chemotherapeutic agent // Biochem. Biophys. Res. Commun. 2008. V. 377. P.1222 - 1226.
  19. Carta De-Angeli L., Pocchiari F., Russi S. et al. Effect of L-asparaginase from Aspergillus terreus on ascites sarcoma in the rat // Nature (London). 1970. V. 225. P. 549 - 550.
  20. Crowther D. L-asparaginase and human malignant disease // Nature. 1971. V. 229. P. 168 - 171.
  21. Derst C., Henseling J., Röhm K.H. Engineering the substrate specificity of Escherichia coli asparaginase II. Selective reduction of glutaminase activity by amino acid replacements at position 248 // Protein Science. 2000. V. 9. P. 2009 - 2017.
  22. Deutsch E., Fischer M., Frischauf H. et al. Blood coagulation changes under L-asparaginase therapy / In: Experimental and clinical effects of L-asparaginase. Ed. E. Grundmann, H.F. Oettgen. Berlin-Heidelberg-NY: Springer-Verlag. 1970. P. 331 - 341.
  23. Distasio J.A., Niederman R.A. Purification and characterization of L-asparaginase with anti-lymphoma activity from Vibrio succinogenes // J. Biol. Chem. 1976. V. 251. № 22. P. 6929 - 6933.
  24. Distasio J.A., Salazar A.M., Nadji M., Durden D.L. Glutaminase-free asparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity // Int. J. Cancer. 1982. V. 30(3). P.343 - 347.
  25. Durden D.L., Salazar A.M., Distasio J.A. Kinetic analisys of hepatotoxicity associated with antineoplastic asparaginases // Cancer Res. 1983. V. 43. P. 1602 - 1605.
  26. Duval M., Suciu S., Ferster A. et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial // Blood. 2002. V. 99. № 8. P. 2734 - 2739.
  27. Eden O.B., Shaw M.P., Lilleyman J.S., Richards S. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia // Med. Pediatr. Oncol. 1990. V. 18(6). P. 497 - 502.
  28. Gaspar M.M., Blanco D., Cruz M.E., Alonso M.J. Formulation of L-asparaginase load poly(lactide-to-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release // J. Controlled Release. 1998. V. 52. P. 53 - 62.
  29. Gaspar M.M., Perez-Soler R., Cruz M.E. Biological characterization of L-asparaginase liposomal formulations // Cancer Chemother. Pharmacol. 1996. V. 38(4). P. 373 - 377.
  30. Gerhartz H., Begemann H. Result of a cooperative study with L-asparaginase in human leukemias / In: Experimental and clinical effects of L-asparaginase. Ed. E. Grundmann, H.F. Oettgen. Berlin-Heidelberg-NY: Springer-Verlag, 1970. P. 244 - 256.
  31. Goldberg A.I., Cooney D.A., Glynn J.P. et al. The effects of immunization to L-asparaginase on antitumor and enzymatic activity // Cancer Res. 1973. V. 33. P. 256 - 261.
  32. Hernández-Espinosa D, Miñano A, Martínez C. et al. L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases // Am. J. Pathol. 2006. V. 169(1). P. 142 - 153.
  33. Howard J.B., Carpenter F.H. L-asparaginase from Erwinia carotovora. Substrate specificity and enzymatic properties // J. Biol. Chem. 1972. V. 247. P.1020 - 1030.
  34. Hunault-Berger M., Chevallier P., Delain M. et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study // Haematologica. 2008. V. 93(10). P. 1488 - 1494.
  35. Jaccard A., Petit B., Girault S. et al. L-aspa¬raginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature // Ann. Oncol. 2009. V. 20. № 1. P. 110 - 116.
  36. Jean-François J., D'Urso E.M., Fortier G. Immobilization of L-asparaginase into a biocompatible poly(ethylene glycol)-albumin hydrogel: evaluation of performance in vivo // Biotechnol. Appl. Biochem. 1997. V. 26(Pt 3). P. 203 - 212.
  37. Jorge J.C., Perez-Soler R., Morais J.G., Cruz M.E. Liposomal palmitoyl-L-asparaginase: characterization and biological activity // Cancer Chemother. Pharmacol. 1994. V. 34(3). P. 230 - 234.
  38. Kearney S.L., Dahlberg S.E., Levy D.E. et al. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis // Pediatr. Blood Cancer. 2009. V. 53(2). P. 162 - 167.
  39. Kelo E., Noronkoski T., Stoineva I.B. et al. Beta-aspartylpeptides as substrates of L-aspa¬raginases from Escherichia coli and Erwinia chrysanthemi // FEBS Lett. 2002. V. 528(1-3). P. 130 - 132.
  40. Khan A., Hill J.M. Atopic hypersensitivity to L-asparaginase: resistance to immunosupression // Int. Arch. Allergy Appl. Immunol. 1971. V. 40. № 3. P. 463 - 569.
  41. Kidd J.G. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum // J. Exp. Med. 1953. V. 98. P. 565 - 582.
  42. Knoderer H.M., Robarge J., Flockhart D.A. Predicting asparaginase-associated pancreatitis // Pediatr. Blood Cancer. 2007. V. 49(5). P. 634 - 639.
  43. Kwon Y.M., Chung H.S., Moon C. et al. L-Aspa¬raginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia // J. Control Release. 2009. V. 139(3). P. 182 - 189.
  44. Leal-Egaña A., Scheibel T. Silk-based materials for biomedical applications // Biotechnol. Appl. Biochem. 2010. V. 55(3). P. 155 - 167.
  45. Mashburn L.T., Wriston J.C. Tumor inhibitory effect of L-asparaginase from E. coli // Arch. Biochem. Biophys. 1964. V. 105. P. 450 - 452.
  46. Moola Z.B., Scawen M.D., Atkinson T., Nicholls D.J. Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes // Biochem. J. 1994. V. 302(Pt 3). P. 921 - 927.
  47. Nowak-Göttl U., Ahlke E., Klösel K. et al. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations // Eur. J. Pediatr. 1997. V. 156(11). P. 848 - 850.
  48. Obama K., Tara M., Niina K. L-asparaginase induced complete remission in Epstein-Barr virus positive, multidrug resistant, cutaneous T-cell lymphoma // Int. J. Hematol. 1999. V. 69. № 4. P. 260 - 262.
  49. Oettgen H.F., Old L.J., Boyse E.A. et al. Inhibition of leukemia in man by L-asparaginase // Cancer Res. 1967. V. 27. P. 2619 - 2631.
  50. Oettgen H.F., Tallal L., Tan C.C. et al. Clinical experience with L-asparaginase / In: Experimental and clinical effects of L-asparaginase. Ed. E. Grundmann, H.F. Oettgen. Berlin-Heidelberg-NY: Springer-Verlag. 1970. P. 219 - 235.
  51. Old L.J., Boyse E.A., Campbell H.A. et al. Treatment of lymphosarcoma in dog with L-asparaginase // Cancer. 1967. V. 20. P. 1066 - 1070.
  52. Ollenschläger G., Roth E., Linkesch W. et al. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects // Eur. J. Clin. Invest. 1988. V. 18(5). P. 512 - 516.
  53. Panosyan E.H., Grigoryan R.S., Avramis I.A. et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961) // Anticancer Res. 2004. V.24(2C). P. 1121 - 1125.
  54. Parsons S.K., Skapek S.X., Neufeld E.J. et al. Asparagianse-associated lipid abnormalities in children with acute lymphoblastic leukemia // Blood. 1997. V. 89. P. 1886 - 1895.
  55. Peterson L.E., Ciegler A. L-asparaginase production by Erwinia aroideae // Appl. Microbiol. 1969. V.18. P. 64 - 67.
  56. Peterson R.G., Handschumacher R.E., Mitchell M.S. Immunologocal responses to L-asparaginase // J. Clin. Invest. 1971. V. 50. P. 1080 - 1090.
  57. Pritsa A.A., Papazisis K.T., Kortsaris A.H. et al. Antitumor activity of L-asparaginase from Thermus thermophilus // Anticancer Drugs. 2001. № 12. P. 137 - 142.
  58. Qian G., Zhou J., Wang D., He B. The chemical modification of E. coli L-asparaginase by N, O-carboxymethyl chitosan // Artif. Cell. Blood Substit. Immobil. Biotechnol. 1996. V. 24. P. 567 - 577.
  59. Reddy V.V.S., Jayaram H.N., Sirsi M., Ramakrishnan T. Inhibitory activity of L-asparaginase from Mycobacterium tuberculosis on Yoshida ascites sarcoma in rats // Arch. Biochem. Biophys. 1969. V.132. P. 262 - 267.
  60. Reinert R.B., Oberle L.M., Wek A.S. et al. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparagine //J. Biol. Chem. 2006. V. 281. P. 31222 - 31233.
  61. Risseeuw-Appel I.M., Dekker I., Hop W.C., Hählen K. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study // Med. Pediatr. Oncol. 1994. V. 23(4). P. 335 - 343.
  62. Roberts J., Schmid F.A., Old L.J., Stockert E. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases // Cancer Biochem Biophys. 1976. V. 1(4). P. 175-178.
  63. Rotoli B.M., Uggeri J., Dall-Asta V. et al. Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells // Cell Physiol. Biochem. 2005. Vol. 15(6). P. 281 - 292.
  64. Spiess K., Lammel A., Scheibel T. Recombinant spider silk proteins for applications in biomaterials // Macromol. Biosci. 2010. V. 10(9). P. 998 - 1007.
  65. Steiner M., Attarbaschi A., Kastner U. et al. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia // Pediatr. Blood Cancer. 2007. V. 9(5). P. 640 - 642.
  66. Steinherz P.G. Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase // Cancer. 1994. V. 74(12). P. 3234 - 3239.
  67. Storti E., Quaglino D. Dysmetabolic and neurological complications in leukemic patients treated with L-asparaginase / In: Experimental and clinical effects of L-asparaginase. Ed. E. Grundmann, H.F. Oettgen. Berlin-Heidelberg-NY: Springer-Verlag. 1970. P. 344 - 349.
  68. Tardito S., Uggeri J., Bozzetto C. et al. The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase // Cancer Chemother. Pharmacol. 2007. V. 60(5). P. 751 - 758.
  69. Tozuka M., Yamauchi K., Hidaka H. et al. Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma // Ann. Clin. Lab. Sci. 1997. V. 27(5). P. 351 - 357.
  70. Uren J.R., Hargis B.J., Beardsley P. Immunological and pharmacological characterization of poly-DL-alanyl-modified Erwinia carotovora L-asparaginase // Cancer Res. 1982. V. 42. P. 4068 - 4071.
  71. Villa P., Corada M., Bartosek I. L-asparaginase effects on inhibition of protein synthesis and lowering of the glutamine content in cultured rat hepatocytes // Toxicol. Lett. 1986. V. 32(3). P.235 - 241.
  72. Vrooman L.M., Supko J.G., Neuberg D.S. et al. Erwinia asparaginase after allergy to E. coli aspar ginase in children with acute lymphoblastic leukemia // Pediatr. Blood Cancer. 2010. V. 54(2). P.199 - 205.
  73. Warrell R.P.Jr., Chou T.C., Gordon C. et al. Phase I evaluation of succinylated Acinetobacter glutaminase-asparaginase in adults // Cancer Res. 1980. V. 40(12). P. 4546 - 4551.
  74. Watanabe S., Miyake K., Ogawa C. et al. The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia // Int. J. Hematol. 2009. V. 90(3). P. 347 - 352.
  75. Woods J.S., Handschumacher R.E. Hepatic homeostasis of plasma L-asparagine // Am. J. Physiol. 1971. V. 221. P. 1785 - 1790.
  76. Yong W., Zheng W., Zhang Y. et al. L-аsparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma // Int. J. Hematol. 2003. V. 78. № 2. P. 163-167.
  77. Zalewska-Szewczyk B., Gach A., Wyka K. et al. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations // Clin. Exp. Med. 2009. № 2. P. 113 - 116.
  78. Zhang Y.Q., Zhou W.L., Shen W.D. et al. Synthesis, characterization and immunogenicity of silk fibroin-L-asparaginase bioconjugates // J. Biotechnol. 2005. V. 120(3). P. 315 - 326.